Amarin reported 122.94M in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
DBV Technologies DBVT:US 19.32M 2.91M
Abbvie ABBV:US $ 8821M 991M
Aerie Pharmaceuticals AERI:US $ 63.48M 552K
Alnylam Pharmaceuticals ALNY:US $ 359.99M 93.1M
Amarin AMRN:US 122.94M 5.42M
AstraZeneca AZN:LN 10.51B 1.79B
Biocryst Pharmaceuticals BCRX:US $ 99.88M 56.38M
Epizyme EPZM:US $ 59.62M 3.25M
Esperion Therapeutics ESPR:US $ 61.82M 9.2M
GlaxoSmithKline GSK:LN 6.98B 1.65B
Halozyme Therapeutics HALO:US $ 41.61M 3.86M
Heron Therapeutics HRTX:US $ 86.38M 12.19M
Intercept Pharmaceuticals ICPT:US $ 98.85M 14.42M
JAZZ PHA JAZZ:US $ 726.17M 121.18M
Nektar Therapeutics NKTR:US $ 141.38M 3.46M
Neurocrine Biosciences NBIX:US $ 307.5M 40.8M
Novartis NOVN:VX 9.96B 998M
Teva Pharmaceutical Industries TEVA:US 4.37B 352M